📰 Dose Management News

Page 3 - Dose Management News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Dose Management. Real-time updates on events, politics, business and more.

FDA Grants Traditional Approval for LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer's Disease

July 7, 2023

/PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge,...

United States New Zealand United Kingdom South Korea Great Britain Haruo Naito

Source: prnewswire.com

FDA Grants Traditional Approval for LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease

July 7, 2023

07.07.2023 - The first and only approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional decline in adults with Alzheimer’s disease The Centers for Medicare & Medicaid Services (CMS) announced broader Medicare ...

United States South Korea United Kingdom New Zealand Great Britain Haruo Naito

Source: wallstreet-online.de

FDA grants traditional approval for LEQEMBI® (lecanemab-irmb) for the treatment of Alzheimer's disease (3)

July 7, 2023

STOCKHOLM, July 7, 2023 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai...

South Korea Uppsala Lan United Kingdom United States Great Britain Oskar Bosson

Source: europapress.es

FDA grants traditional approval for LEQEMBI® (lecanemab-irmb) for the treatment of Alzheimer's disease (2)

July 7, 2023

STOCKHOLM, July 7, 2023 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai...

United Kingdom United States Uppsala Lan South Korea Great Britain Gunilla Osswald

Source: europapress.es

FDA grants traditional approval for LEQEMBI® (lecanemab-irmb) for the treatment of Alzheimer's disease

July 7, 2023

/PRNewswire/ -- BioArctic ABs (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that the U.S. Food and Drug Administration, FDA, has approved...

Uppsala Lan United States United Kingdom South Korea Great Britain Oskar Bosson

Source: prnewswire.com

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease

June 10, 2023

10.06.2023 - Peripheral and Central Nervous System Drugs Advisory Committee voted based on data from large global confirmatory Phase 3 Clarity AD clinical trial in patients living with early Alzheimer’s disease The PDUFA action date for traditional approval ...

South Korea United States New Zealand United Kingdom Great Britain Jack Cox

Source: wallstreet-online.de

FDA Advisory Committee votes unanimously to confirm clinical benefit of LEQEMBI® (lecanemab-irmb) for the treatment of e

June 10, 2023

STOCKHOLM, June 10, 2023 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai...

South Korea Uppsala Lan United States Oskar Bosson Drug Administration Alzheimer Clinical Trial Consortium

Source: europapress.es

FDA Advisory Committee votes unanimously to confirm clinical benefit of LEQEMBI® (lecanemab-irmb) for the treatment of early Alzheimer's disease

June 10, 2023

/PRNewswire/ -- BioArctic ABs (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the U.S. Food and Drug Administrations (FDA) Peripheral...

Uppsala Lan United States South Korea Oskar Bosson National Institute On Drug Administration

Source: prnewswire.com

BioArctic: FDA Advisory Committee votes unanimously to confirm clinical benefit of LEQEMBI® (lecanemab-irmb) for the treatment of early Alzheimer's disease

June 10, 2023

STOCKHOLM, June 10, 2023 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the U.S. Food and Drug Administration's (FDA) Peripheral and Central

Uppsala Lan South Korea United States Oskar Bosson Health Canada On Ministry Of Health

Source: finanznachrichten.de